Evidence map›Paper›PMID 37975903›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2024

PRESSING Need of Precision Care in HER2-Positive Colorectal Cancer: The ELEPHANT in the Room.

Kanwal P S Raghav, Jonathan M Loree, Scott Kopetz

Abstract readComment
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients WithJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Trial
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Kanwal P S RaghavDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-1311-4173
Jonathan M LoreeBC Cancer, University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0001-8189-2132
Scott KopetzDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-9647-3416

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Although dual HER2 inhibition has shown promising clinical activity in patients with RAS wild-type HER2-positive metastatic colorectal cancer, predictive biomarkers of response/resistance are less well characterized. Activating HER2/RTK/MAPK genomic alterations appears to blunt the clinical benefit of dual anti-HER2 therapy and may hold a potential albeit partial role in patient selection. See related article by Randon et al., p. 436.

Indexed as

Colorectal NeoplasmsErb-b2 Receptor Tyrosine KinasesBiomarkers, TumorHumansBiomarkers, TumorErb-b2 Receptor Tyrosine Kinases

Identifiers

PMID37975903
PMCPMC10841812

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.